The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.
作者信息
Franceschi Enrico, Brandes Alba A
机构信息
Medical Oncology Department, Bellaria Maggiore Hospitals, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy.
出版信息
CNS Oncol. 2015;4(3):117-9. doi: 10.2217/cns.15.7. Epub 2015 Apr 23.
Abstract
摘要
相似文献
1
The role of bevacizumab in recurrent glioblastoma: new insights from randomized trials.贝伐单抗在复发性胶质母细胞瘤中的作用：来自随机试验的新见解。
CNS Oncol. 2015;4(3):117-9. doi: 10.2217/cns.15.7. Epub 2015 Apr 23.
2
Renewing interest in targeting angiogenesis in glioblastoma.对胶质母细胞瘤中血管生成靶向治疗的兴趣再度兴起。
Lancet Oncol. 2014 Aug;15(9):907-8. doi: 10.1016/S1470-2045(14)70329-8. Epub 2014 Jul 15.
3
Bevacizumab alone or in combination with chemotherapy in glioblastomas?
Lancet Oncol. 2014 Oct;15(11):e472-3. doi: 10.1016/S1470-2045(14)70396-1.
4
Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authors' reply.
Lancet Oncol. 2014 Oct;15(11):e473-4. doi: 10.1016/S1470-2045(14)70453-X.
5
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.贝伐珠单抗单药或洛莫司汀单药与贝伐珠单抗联合洛莫司汀治疗复发性胶质母细胞瘤患者的比较（BELOB 试验）：一项随机对照 2 期试验。
Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.
6
CNS cancer: it takes two to tango.
Nat Rev Clin Oncol. 2014 Sep;11(9):502. doi: 10.1038/nrclinonc.2014.133. Epub 2014 Aug 5.
7
Neuro-oncology: It takes two to tango.
Nat Rev Neurol. 2014 Sep;10(9):484. doi: 10.1038/nrneurol.2014.150. Epub 2014 Aug 19.
8
Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.对于贝伐单抗难治性复发性胶质母细胞瘤添加洛莫司汀。
Acta Oncol. 2014 Oct;53(10):1436-40. doi: 10.3109/0284186X.2014.920960. Epub 2014 May 26.
9
Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.复发性胶质母细胞瘤患者随机接受贝伐单抗联合洛莫司汀、贝伐单抗单药或洛莫司汀单药治疗时循环内皮细胞的预后价值及动力学。荷兰神经肿瘤学组BELOB试验报告
Br J Cancer. 2015 Jul 14;113(2):226-31. doi: 10.1038/bjc.2015.191. Epub 2015 Jun 4.
10
[Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].[24例胶质母细胞瘤放化疗后复发并接受亚硝基脲类药物或伊立替康及贝伐单抗治疗的回顾性分析]
Bull Cancer. 2012 Feb 1;99(2):121-6. doi: 10.1684/bdc.2011.1528.
引用本文的文献
1
Glioblastoma Therapy: Past, Present and Future.胶质母细胞瘤治疗：过去、现在和未来。
Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529.
2
Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model.成人复发性胶质母细胞瘤患者生存的预后因素：基于决策树的模型。
J Neurooncol. 2018 Feb;136(3):565-576. doi: 10.1007/s11060-017-2685-4. Epub 2017 Nov 20.
3
Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.复发性胶质母细胞瘤：初始复发及后续复发的治疗策略
Curr Treat Options Oncol. 2016 Sep;17(9):49. doi: 10.1007/s11864-016-0422-4.
本文引用的文献
1
Practical management of bevacizumab-related toxicities in glioblastoma.胶质母细胞瘤中贝伐单抗相关毒性的实际管理
Oncologist. 2015 Feb;20(2):166-75. doi: 10.1634/theoncologist.2014-0330. Epub 2015 Jan 7.
2
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.贝伐珠单抗单药或洛莫司汀单药与贝伐珠单抗联合洛莫司汀治疗复发性胶质母细胞瘤患者的比较（BELOB 试验）：一项随机对照 2 期试验。
Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.
3
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.无进展生存期作为胶质母细胞瘤总生存期的替代终点：基于91项试验的文献荟萃分析
Neuro Oncol. 2014 May;16(5):696-706. doi: 10.1093/neuonc/not236. Epub 2013 Dec 12.
4
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.III 期随机临床试验比较西地尼布单药治疗与联合洛莫司汀对比洛莫司汀单药治疗复发性胶质母细胞瘤患者的疗效。
J Clin Oncol. 2013 Sep 10;31(26):3212-8. doi: 10.1200/JCO.2012.47.2464. Epub 2013 Aug 12.
5
Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma.抗血管生成药物时代的恰当终点：复发性胶质母细胞瘤患者 II 期试验的未来选择。
Eur J Cancer. 2012 Apr;48(6):896-903. doi: 10.1016/j.ejca.2011.10.027. Epub 2011 Nov 24.
6
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.贝伐珠单抗治疗复发性胶质母细胞瘤患者的生存反应预测。
Neuro Oncol. 2011 Jan;13(1):143-51. doi: 10.1093/neuonc/noq151. Epub 2010 Nov 17.
7
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.高级别胶质瘤更新后的反应评估标准：神经肿瘤学工作组的反应评估。
J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.
8
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.恩杂鲁胺对比洛莫司汀治疗复发性颅内胶质母细胞瘤的 III 期研究。
J Clin Oncol. 2010 Mar 1;28(7):1168-74. doi: 10.1200/JCO.2009.23.2595. Epub 2010 Feb 1.
9
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.贝伐单抗单药及联合伊立替康治疗复发性胶质母细胞瘤。
J Clin Oncol. 2009 Oct 1;27(28):4733-40. doi: 10.1200/JCO.2008.19.8721. Epub 2009 Aug 31.
10
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).福莫司汀作为替莫唑胺同步和/或辅助治疗后复发或进展性胶质母细胞瘤的二线治疗：意大利神经肿瘤协作组（GICNO）的II期试验
Cancer Chemother Pharmacol. 2009 Sep;64(4):769-75. doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24.
Zotero 插件